Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Normally when people have B-cell lymphoma that is not in complete remission, they do not immediately have another treatment. They have observation. That means their doctor closely monitors their disease with imaging tests to see if their disease is improving or worsening. If their disease gets worse, they may receive more treatment.
In this study, researchers are assessing the safety and effectiveness of using the drug ruxolitinib in patients with T-cell lymphoma or natural killer (NK)-cell lymphoma that has come back or continued to grow despite prior treatment. Ruxolitinib is already approved for treating a bone marrow disease called myelofibrosis. It works by inhibiting a protein called JAK, which works with another protein called STAT to promote the growth of many T-cell and NK-cell lymphomas. By blocking JAK, ruxolitinib may cause lymphomas to shrink.
The purpose of this study is to assess the safety and effectiveness of giving the investigational immunotherapy drug INCMGA00012 in combination with gemcitabine and docetaxel in patients with inoperable or metastatic soft tissue sarcoma. Gemcitabine and docetaxel are standard treatments for this disease; researchers believe that adding INCMGA00012 may make treatment more effective.
Researchers want to learn if giving ivosidenib with other drugs is safe and works well in people with advanced cholangiocarcinoma. The people in this study have cholangiocarcinoma that has metastasized (spread) and is inoperable (cannot be removed with surgery). Their tumors have a mutation (change) in the IDH1 gene.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers are assessing a new treatment for people with prostate cancer that has not spread but has a high risk of spreading. The new treatment, 2141-V11, will be given with standard prostate cancer therapies.
Atezolizumab is a standard treatment for extensive-stage small cell lung cancer (SCLC, cancer which has spread). Researchers want to see if adding valemetostat to atezolizumab therapy is safe for people with SCLC. The people in this study have extensive-stage SCLC and have completed 4 treatment cycles of atezolizumab with chemotherapy.
Researchers want to find the best dose of INCA033989 to use in people with myelofibrosis (MF) and essential thrombocytopenia (ET). These diseases are called myeloproliferative neoplasms. The people in this study have myeloproliferative neoplasms that came back or keep growing even after treatment. In addition, their cancers have a mutation (change or variant) in the CALR exon-9 gene.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
